Fig. 6

NF-κB activated pyroptosis-associated proteins treatment with IL-17A. A-B Protein levels of NF-κB p65, caspase 1, caspase 4, NLRP3, ASC, IL-1β, IL-18 and and GSDMD-N in CRC cells treated with IL-17A (100 ng/ml) for 72 h, data conforms to normal distribution, and tested by two independent samples t-test; C Representative IF staining of NLRP3 and ASC in CRC cells treated with IL-17A (100 ng/ml) for 72 h; D Representative microscopic images of CRC cells treated with IL-17A (100 ng/ml) and Z-YVAD(50 μM) or Z-LEVD(50 μM) or TEMPO(10 μM) for 72 h. Red arrows indicate the characteristic balloon in the cell membrane; E Protein levels of NF-κB p65, caspase1, caspase4, NLRP3, ASC, IL-1β, IL-18 and and GSDMD-N in CRC cells treated with IL-17A (100 ng/ml) and different types of inhibitors for 72 h